fda advisory_committee_meeting
saveAstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)
community read0 votes
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer
Data sources
globaldata
Found something off?
drug timeline · 4
same company · ±60 days · 6
- phase 1 2 completionCALQUENCE: AstraZeneca Plc — Calquence (Phase I/II Trial Completion)Apr 30, 2026
- fda advisory committee meetingcamizestrant: AstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)Apr 30, 2026
- phase 2 completiontozorakimab: AstraZeneca Plc — tozorakimab (Phase II Trial Completion)Apr 30, 2026
- phase 3 completiondurvalumab: AstraZeneca Plc — durvalumab (Phase III Trial Completion)Apr 29, 2026
- earningsASTRAZENECA PLC earningsApr 29, 2026
- approvaleplontersen sodium: WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approvalApr 15, 2026
comments(0)
5-min edit window · permanent after that